Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890875 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT02890875: Clinical Trial NA study, sponsored by Stanford University.
NCT02890875 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02890875, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.
Interventions
- OTHER Ethanol lock
- OTHER Heparin lock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02890875
The ClinicalTrials.gov registry entry for NCT02890875 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ethanol lock is the first listed.
NCT02890875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02890875 about?
NCT02890875 is a clinical study titled "Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections". Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.
What is the current status of trial NCT02890875?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2016-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02890875?
The interventions under investigation include: Ethanol lock (OTHER), Heparin lock (OTHER).
Who is sponsoring clinical trial NCT02890875?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.